Table 3.
Comparison of the keratin variant frequency in patients with IBD and the controls.
| Variant | No. of Variant Carriers/Total (%) | p-Value | Ref. | |||
|---|---|---|---|---|---|---|
| UC Cohort | CD Cohort | IBD Cohort (UC + CD) |
Controls | |||
| K8 G62C | 8/348 (2.3) |
6/555 (1.1) |
13/866 a (1.5) |
6/273 (2.2) |
ND | [13] |
| 2/32 (6.3) |
1/57 (1.8) |
3/89 (3.4) |
1/97 (1.0) |
ND | [14] | |
| 3/131 (2.3) |
5/217 (2.3) |
8/348 (2.3) |
9/560 (1.6) |
p > 0.05 | [55] | |
| K8 Y54H | 0/131 (0.0) |
0/217 (0.0) |
0/348 (0.0) |
0/560 (0.0) |
ND | [55] |
| K8 R341H/C | 14/348 (4.0) |
24/555 (4.3) |
37/866 a (4.3) |
11/273 (4.0) |
ND | [13] |
| K19 Promoter | 34/100 (34.0) |
37/100 (37.0) |
71/200 (35.5) |
33/70 (47.1) |
ND | [13] |
a The numbers for IBD cohort are less than the sum of the UC + CD cohort, because each sibling in group II UC-CD sibling pair is counted in either UC or CD cohort, but only one of these siblings is counted in the IBD cohort [13]. ND, not determined.